PrLZ is expressed in normal prostate development and in human prostate cancer progression

Clinical Cancer Research

Volumn 13, Issue 20, 2007, Pages 6040-6048

  Wang, Ruoxiang ^a   Xu, Jianchun ^a   Mabjeesh, Nicola ^b   Zhu, Guodong ^c   Zhou, Jianguang ^d   Amin, Mahul ^a   He, Dalin ^c   Marshall, Fray F ^a   Zhau, Haiyen E ^a   Chung, Leland W K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^d BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN PRLZ; UNCLASSIFIED DRUG;

ARTICLE; BONE METASTASIS; CANCER GROWTH; CELL SPECIFICITY; CELL STRUCTURE; CHROMOSOME 8Q; CONTROLLED STUDY; DISEASE MARKER; EMBRYO DEVELOPMENT; GENE EXPRESSION REGULATION; GENE ISOLATION; GENE LOCUS; GENE OVEREXPRESSION; GESTATIONAL AGE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL DETECTION; TUMOR LOCALIZATION;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; TRANSFECTION;

EID: 35948961547     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0640     Document Type: Article

References (33)

1. Wang R, Xu J, Saramaki O, et al. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 2004;64:1589-94.
2. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
3. Byrne JA, Tomasetto C, Garnier JM, et al. A screening method to identify genes commonly overexpressed in carcinomas and the identification of a novel complementary DNA sequence. Cancer Res 1995;55:2896-903.
4. Chen SL, Zhang XK, Halverson DO, et al. Characterization of human N8 protein. Oncogene 1997;15:2577-88.
5. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998;153:141-8.
6. Zhau HY, Chang SM, Chen BQ, et al. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci US A1996;93:15152-7.
7. Zhu G, Zhau HE, He H, et al. Sonic and desert hedgehog signaling in human fetal prostate development. Prostate 2007;67:674-84.
8. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002;26:312-9.
9. Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 1996;88:794-801.
10. Kajiwara T, Takeuchi T, Ueki T, et al. Effect of Bcl-2 overexpression in human prostate cancer cells in vitro and in vivo. Int J Urol 1999;6:520-5.
11. Sun SY, Zhou Z, Wang R, Fu H, Khuri FR. The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without down-regulation of Akt. Cancer Biol Ther 2004;3:1092-8; discussion 9-101.
12. + exchanger in hypoxia/re-oxygenation-induced neonatal rat cardiomyocyte apoptosis. Eur J Pharmacol 2004;486:121-31.
13. Xu J, Wang R, Xie ZH, et al. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 2006;66:1664-73.
14. Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001;61:6012-9.
15. Sathasivam P, Bailey AM, Crossley M, Byrne JA. The role of the coiled-coil motif in interactions-mediated by TPD52. Biochem Biophys Res Commun 2001;288:56-61.
16. Nourse CR, Mattei MG, Gunning P, Byrne JA. Cloning of a third member of the D52 gene family indicates alternative coding sequence usage in D52-like transcripts. Biochim Biophys Acta 1998;1443:155-68.
17. Byrne JA, Mattei MG, Basset P. Definition of the tumor protein D52 (TPD52) gene family through cloning of D52 homologues in human (hD53) and mouse (mD52). Genomics 1996;35:523-32.
18. Cinar B, Yeung F, Konaka H, et al. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-κB signalling in prostate cancer cells. Biochem J 2004;379:421-31.
19. Ye Q, Cinar B, Edlund M, Chung LW, Zhau HE. Inhibition of growth and cell cycle arrest of ARCaP human prostate cancer cells by ectopic expression of ER-α. Mol Cell Biochem 2001;228:105-10.
20. Cunha GR, Ricke W, Thomson A, et al. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 2004;92:221-36.
21. Xue Y, Sonke G, Schoots C, et al. Proliferative activity and branching morphogenesis in the human prostate: a closer look at pre- and postnatal prostate growth. Prostate 2001;49:132-9.
22. 2+-sensitive CRHSP-28-binding protein in pancreatic acinar cells. J Biol Chem 2002;277:35496-502.
23. Diver MJ. Analytical and physiological factors affecting the interpretation of serum testosterone concentration in men. Ann Clin Biochem 2006;43:3-12.
24. Brann DW, Mahesh VB. The aging reproductive neuroendocrine axis. Steroids 2005;70:273-83.
25. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257-75.
26. Hyytinen ER, Thalmann GN, Zhau HE, et al. Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br J Cancer 1997;75:190-5.
27. Deschamps J, Meijlink F. Mammalian homeobox genes in normal development and neoplasia. Crit Rev Oncog 1992;3:117-73.
28. Kenney NJ, Adkins HB, Sanicola M. Nodal and Cripto-1: embryonic pattern formation genes involved in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2004;9:133-44.
29. Ming JE, Roessler E, Muenke M. Human developmental disorders and the Sonic hedgehog pathway. Mol Med Today 1998;4:343-9.
30. Busch SJ, Sassone-Corsi P. Dimers, leucine zippers and DNA-binding domains. Trends Genet 1990;6:36-40.
31. Boutros R, Bailey AM, Wilson SH, Byrne JA. Alternative splicing as a mechanism for regulating 14-3-3 binding: interactions between hD53 (TPD52L1) and 14-3-3 proteins. J Mol Biol 2003;332:675-87.
32. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006;16:203-13.
33. van Heusden GP. 14-3-3 proteins: regulators of numerous eukaryotic proteins. IUBMB Life 2005;57:623-9.